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Abstract
Background: Data on the effects of folic acid supplementation on clinical symptoms and metabolic profiles of patients with 
endometrial hyperplasia (EH) are limited. This investigation was performed to evaluate the effects of folic acid supplementation on 
clinical symptoms and metabolic status of patients with EH.
Methods: This randomized, double-blind, placebo-controlled trial was conducted among 60 women diagnosed with EH. Diagnosis 
of EH was made based on biopsy results. Participants were randomly allocated to 2 groups to take 5 mg/d folic acid supplements 
(n = 30) or placebo (n = 30) for 12 weeks. 
Results: After the 12-week intervention, folic acid supplementation significantly decreased fasting plasma glucose (β -3.99 mg/
dL; 95% CI, -7.39, -0.59; P = 0.02), serum insulin levels (β -2.82 µIU/mL; 95% CI, -4.86, -0.77; P = 0.008), homeostasis model 
assessment for insulin resistance (β -0.68; 95% CI, -1.20, -0.17; P = 0.009), triglycerides (β -16.47 mg/dL; 95% CI, -28.72, -4.22; 
P = 0.009) and very-low-density lipoprotein (VLDL) cholesterol (β -3.29 mg/dL; 95% CI, -5.74, -0.84; P = 0.009), and significantly 
increased the quantitative insulin sensitivity check index (β 0.01; 95% CI, 0.004, 0.03; P = 0.01) compared with the placebo. 
Additionally, folic acid intake resulted in a significant reduction in serum high sensitivity C-reactive protein (hs-CRP) (β -0.36 
mg/L; 95% CI, -0.52, -0.21; P < 0.001) compared with the placebo. Folic acid supplementation did not affect other metabolic 
parameters. 
Conclusion: In conclusion, we found that folic acid administration for 12 weeks to subjects with EH improved glycemic control, 
triglycerides, VLDL-cholesterol and hs-CRP levels, but did not influence recurrence and other metabolic profiles. 
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Introduction
Endometrial hyperplasia (EH) is a precursor to the most 
common female gynecologic diseases with a high risk for 
malignant transformations and relapses.1 EH may result 
in endometrial cancer in up to 50% of cases.2 Most cases 
of EH are due to unopposed, prolonged exposure of the 
endometrium to oestrogen.3 In addition, some studies 
have reported the association between insulin resistance, 
inflammation and oxidative stress, and the progression of 
EH. In a study by Mitsuhashi et al,4 it was observed that 
abnormal glucose metabolism and insulin resistance were 
highly prevalent in patients with EH and endometrial 
cancer. Increased inflammatory cytokines also increase the 
incidence of complex and atypical EH.5
Previous studies have shown that folic acid deficiency is 
associated with several abnormalities including breaking 
DNA strand, enhanced mutation rates and impaired DNA 
repair mechanisms.6,7 Data on the association between 
folic acid deficiency and EH are sparse and inconsistent. 
Animal experimental and epidemiological studies have 
demonstrated an association between the increased risk 
of various cancers and folic acid deficiency.8,9 The results 
of another study showed a significant inverse association 
between dietary folic acid intake and endometrial cancer risk 
among all subjects and non-B vitamin supplement users.10 
However, higher dietary folic acid intake was associated with 
a modestly decreased risk of ovarian cancer.11 In addition, 
improvement in insulin sensitivity was observed following 
supplementation with 2.5 mg/d folic acid for 12 weeks 
among overweight subjects.12 In addition, we have previously 
shown that folic acid supplementation (5 mg/d) in subjects 
with polycystic ovary syndrome (PCOS) had beneficial 
effects on biomarkers of inflammation and oxidative stress.13
Folic acid intake may reduce cancer risk through increased 
Open 
Access 
                                                                                                     Arch Iran Med, Volume 21, Issue 10, October 2018  453
Folic Acid Supplementation and Endometrial Hyperplasia
5-methyltetrahydrofolic acid availability, increased values of 
methionine, and global hypomethylation of DNA.14,15 This 
evidence might suggest the beneficial effects of folic acid 
administration in control of proliferation in EH. Although 
there is no specific data on the prevalence of folic acid 
deficiency in Iranian women with EH, we expect a high rate 
of deficiency in these patients due to the low consumption 
of fruits and vegetables in Iranian diet. Mean daily intake 
of folic acid among women of childbearing age in Iran has 
been reported to be 198.3 µg/d,16 which is much lower than 
recommendation. Therefore, based on existing evidence, 
we hypothesized that clinical signs, metabolic profiles and 
biomarkers of inflammation and oxidative stress might be 
improved by folic acid supplementation in patients with 
EH. The aim of the current study was to evaluate the effects 
of folic acid supplementation on recurrence and metabolic 
status of patients with EH.
Materials and Methods
Participants
This randomized, double-blind, placebo-controlled clinical 
trial, registered in the Iranian website for registration of 
clinical trials (identifier: IRCT2016060122562N2; http://
www.irct.ir), was carried out among 60 subjects with EH 
who were diagnosed with endometrial biopsy in the past 
year, aged 35–55 years old and referred to the Naghavi 
Clinic in Kashan, Iran, from October 2016 to January 2017. 
Exclusion criteria were smoking, unwilling to cooperate, 
menopausal women, history of cardiovascular diseases, 
diabetes mellitus, hypertension and untreated thyroid 
diseases.
Study Design
At the beginning of the study, to decrease potential 
confounding effects, randomization was stratified according 
to age and body mass index (BMI). Then, participants in 
each block were randomly allocated into 2 treatment groups 
to take either 5 mg folic acid (Tehran Darou, Tehran, 
Iran) or placebo (Barij Essence, Kashan, Iran) (n = 30 each 
group) per day for 12 weeks. All study participants followed 
the standard treatment protocol, consuming 5 mg/d 
medroxyprogesterone (2 weeks/month) for 12 weeks.17 
Duration of intervention was used based on observed 
beneficial effects of folic acid supplements on metabolic 
status in patients with PCOS.13 Both folic acid supplements 
and placebo (starch) tablets had similar packaging and 
patients and researchers were unaware of the content of the 
package until the end of study. Compliance was evaluated 
by counting the remaining supplements and placebos, 
and subtracting them from the number of supplements 
provided to the participants. To increase compliance rate, 
all subjects received reminder messages on their cell phones 
every day to remind them to take their capsules. In addition, 
compliance to the folic acid supplementation was assessed 
through quantification of plasma total homocysteine (tHcy) 
levels. All patients completed 3-day food records and three 
physical activity records as metabolic equivalents (METs) 
in hours per day18 at baseline, weeks 3, 6, 9 and 12 of the 
intervention. Daily macro- and micro-nutrient intakes were 
analyzed by nutritionist IV software (First Databank, San 
Bruno, CA). 
Assessment of Anthropometric Measures
A trained midwife at the gynecology clinic took 
anthropometric measurements at baseline and 12 weeks 
following the intervention. Weight (Seca, Hamburg, 
Germany) was measured in an overnight fasting status 
without shoes in a minimal clothing state. BMI was 
calculated as weight in kg divided by height in meters 
squared. 
Outcomes
EH recurrence and high sensitivity C-reactive protein (hs-
CRP) were considered as the primary study variables, and 
markers of insulin metabolism, lipid profiles, biomarkers 
of inflammation and oxidative stress were considered as 
secondary outcomes.
Clinical Assessment 
Diagnosis of EH was made based on biopsy results at 
baseline and after the 12-week intervention. Endometrial 
biopsies were done using suction pipelles, fixed in 10% 
neutral buffered formalin, routinely processed, and 
paraffin embedded. Serial 5 micron sections were stained 
with hematoxylin and eosin and evaluated under the light 
microscope by a pathologist. Assessment of the pathological 
diagnosis was performed as concealment by a single 
experienced pathologist at baseline and at the end of the 
trial. Informed consent was taken from all participants for 
biopsy both at baseline and after the 12-week intervention.
Biochemical Assessment
At baseline and 12 weeks after the intervention, 10 mL 
fasting blood samples were taken from each patient at 
the Kashan reference laboratory, Kashan, Iran. Blood 
samples were immediately centrifuged (Hettich D-78532, 
Tuttlingen, Germany) at 3500 rpm for 10 minutes to 
separate the serum. The samples were then stored at -80°C 
until being analyzed at the Kashan reference laboratory. 
Plasma tHcy was assessed using an enzyme immunoassay 
method by tHcy kit (Axis-Shield Diagnostics, UK). Serum 
insulin concentrations were measured using an ELISA 
kit (DiaMetra, Milano, Italy) with intra- and inter-assay 
coefficient variances (CVs) of 2.5 and 4.3%, respectively. 
The homeostasis model assessment for insulin resistance 
(HOMA-IR) and the quantitative insulin sensitivity 
check index (QUICKI) were determined according to the 
suggested formulas.19 Enzymatic kits (Pars Azmun, Tehran, 
Iran) were used to quantify fasting plasma glucose (FPG) 
and lipid profiles. Serum hs-CRP concentrations were 
quantified by an ELISA kit (LDN, Nordhorn, Germany). 
The plasma nitric oxide (NO) concentrations were assessed 
using Griess method.20 Plasma total antioxidant capacity 
(TAC) concentrations were evaluated by the method of 
ferric reducing antioxidant power developed by Benzie and 
Strain21; total glutathione (GSH) was evaluated using the 
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method of Beutler et al22 and malondialdehyde (MDA) 
concentrations were assessed by the thiobarbituric acid 
reactive substances spectrophotometric test.23 All inter- and 
intra-assay CVs for FPG, lipid fractions, hs-CRP, NO, TAC, 
GSH and MDA concentrations were less than 6%. 
Randomization
Randomization assignment was conducted using computer-
generated random numbers. Randomization and allocation 
were concealed from both researchers and patients until the 
final analyses were completed. The randomized allocation 
sequence, enrolling patients and allocating them to 
interventions were performed by a trained member at the 
gynecology clinic.
Sample Size
Sample size was calculated using the formula suggested for 
randomized clinical trials. EH recurrence and hs-CRP were 
considered as the primary study variables; therefore, we used 
hs-CRP to calculate sample size. Type one (α) and type 2 (β) 
errors were defined as 0.05 and 0.20, with the study power 
of 80%. Based on a previous study,13 we used 0.29 mg/dL 
as SD. In addition, 0.23 mg/dL was considered as effect 
size (the mean difference) of the hs-CRP. Based on this, we 
needed 25 patients in each treatment group. Allowing 20% 
dropouts in each group, the final sample size was considered 
to be 30 patients in each group.
Statistical Methods
The Kolmogorov-Smirnov test was done to determine the 
normality of data. To detect the differences in anthropometric 
measures and dietary intakes between treatment groups, 
we used the independent-samples t-test. Multiple linear 
regression model was used to assess the intention-to-treat 
effect of treatment on study outcomes after adjusting for 
random confounding by the baseline values of outcome, 
age, and BMI.24 The effect sizes were presented as mean 
differences with 95% confidence intervals. Outcome log-
transformation was used if model residual had non-normal 
distribution (tHcy, hs-CRP and QUICKI). P-values <0.05 
were considered statistically significant. All statistical 
analyses were done using the Statistical Package for Social 
Science version 18 (SPSS Inc., Chicago, Illinois, USA).
Results
At baseline, we recruited 75 subjects; however, 15 subjects 
were excluded from the study because of not meeting the 
inclusion criteria. Sixty participants (folic acid [n = 30] and 
placebo [n = 30]) completed the trial (Figure 1). On average, 
the rate of compliance in the present study was high, and 
more than 90% of supplements were taken throughout the 
study in both groups. No side effects were reported following 
supplementation with folic acid in subjects with EH.
Mean age, height, baseline weight and BMI as well as 
their means before and after the 12-week treatment were not 
statistically different between folic acid and placebo groups 
(Table 1). In addition, taking folic acid for 12 weeks did not 
affect EH recurrence. 
Based on the 3-day dietary records obtained throughout 
the trial, we found no signiﬁcant difference in mean macro- 
and micronutrient intakes between 2 groups (Table 2).
After the 12-week intervention, folic acid supplementation 
significantly decreased FPG (β -3.99 mg/dL; 95% CI, 
-7.39, -0.59; P = 0.02), serum insulin levels (β -2.82 µIU/
mL; 95% CI, -4.86, -0.77; P = 0.008), HOMA-IR (β 
-0.68; 95% CI, -1.20, -0.17; P = 0.009), triglycerides (β 
-16.47 mg/dL; 95% CI, -28.72, -4.22; P = 0.009) and very-
low-density lipoprotein (VLDL) cholesterol (β -3.29 mg/
dL; 95% CI, -5.74, -0.84; P = 0.009), and significantly 
increased QUICKI (β 0.01; 95% CI, 0.004, 0.03; P = 0.01) 
compared with the placebo (Table 3). Additionally, folic acid 
intake resulted in a significant reduction in serum hs-CRP 
Figure 1. Summary of Patients’ Flow Diagram.
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method of Beutler et l22 and malondialdehyde (MDA) 
concentrations were assessed by t e thiobarbituric acid 
reactive substanc s spectrophotometric test.23 All inter- and 
intr -assay CVs for FPG, lipid fractions, hs-CRP, NO, TAC, 
GSH and MDA concentrations w re less than 6%. 
Randomization
Randomization assig ment was conducted using computer-
generated random numbers. Randomization nd allocation 
were concealed from both resea chers and patients until the 
final analys s were completed. The randomized allocation 
sequence, enrolling patients and llocating them to 
interve tions were performed by a trained m mber at the 
gynecology linic.
Sampl  Size
Sampl  size was c lculated using the form la suggested for 
randomized linic l trials. EH ecurrence and hs-CRP were 
consi ered as the p imary study variables; therefor , we used 
hs-CRP to c lcul te sampl  size. Typ one (α) and type 2 (β) 
errors were defined as 0.05 and 0.20, with the study power 
of 80%. Based on a previo s study,13 w  used 0.29 mg/dL 
as SD. In addition, 0.23 mg/dL was consi ered as effect 
siz (the mean difference) of the hs-CRP. Based on this, we 
needed 25 patie ts in each treatment group. Allowing 20% 
dropouts in each group, the final sampl  size was consi ered 
to be 30 patie ts in each group.
Statistical Methods
The Kolm gorov-Smirnov test was done to determine the 
normality of data. To detect the differences in anthropometric 
measures and dietary intakes between treatment groups, 
we used the independent-samples t-test. Multiple linear 
regression model was used to assess the intention-to-treat 
effect of treatment on study outcomes after adjusting for 
random confounding by the baseline values of outcome, 
age, and BMI.24 The effect sizes were presented as mean 
differences with 95% confidence intervals. Outcome log-
transformation was used if model residu l had non-normal 
distribution (tHcy, hs-CRP and QUICKI). P-values <0.05 
were consi ered atistically significant. All statistical 
analyses were done using the Statistic l Package for Social 
S ience version 18 ( PSS Inc., Chicago, Illinois, USA).
Re ults
At baselin , we recruited 75 subjects; however, 15 subjects 
w re excluded from the study because of not meeting the 
inclusion criteria. Sixty participants (folic acid [n = 30] and 
placebo [n = 30]) comple ed he trial (Figure 1). On verage, 
the rate f compliance in th  present study was high, and 
more than 90% of supplements were taken throughout the 
study in both groups. No sid  effects were reported following 
supplementation with folic acid in subjects with EH.
Mean ag , eight, bas lin  weight and BMI as well as 
their means b fore nd after the 12-week reatment were not 
atistically differen  between folic acid and placeb  groups 
(Table 1). In addition, taking folic acid for 12 weeks did not 
affect EH ecurrence. 
Based on the 3- ay dietary records obtained throughout 
the trial, we found no signiﬁcant difference in mean macro- 
and micronutrie t intak s between 2 groups (Table 2).
After the 12-week interve tion, folic acid supplementation 
significantly decreased FPG (β -3.99 mg/dL; 95% CI, 
-7.39, -0.59; P = 0.02), serum insulin levels (β -2.82 µIU/
mL; 95% CI, -4.86, -0.77; P = 0.008), HOMA-IR (β 
-0.68; 95% CI, -1.2 , -0.17; P = 0.009), triglycerides (β 
-16.47 mg/dL; 95% CI, -28.72, -4.22; P = 0.009) and very-
low-density lipoprotein (V DL) cholesterol (β -3.29 mg/
dL; 95% CI, -5.74, -0.84; P = 0.009), and significantly 
increased QUICKI (β 0.01; 95% CI, 0.004, 0.03; P = 0.01) 
compared with the placebo (Table 3). Additionally, folic acid 
intake resulted in a significant reduction in serum hs-CRP 
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(β -0.36 mg/L; 95% CI, -0.52, -0.21; P < 0.001) compared 
with the placebo. Folic acid supplementation did not affect 
other metabolic parameters. 
Discussion
To our knowledge, the beneficial effects of folic acid 
administration on recurrence and metabolic status of EH 
have not been evaluated previously. For the first time, we 
found that folic acid supplementation at a dosage of 5 
mg/d for patients with EH improved glycemic control, 
triglycerides, VLDL-cholesterol and hs-CRP levels, but did 
not influence recurrence and other metabolic profiles. 
Effects on EH Recurrence 
Subjects with EH are susceptible to endometrial cancer.2 We 
found that folic acid supplementation for patients with EH 
did not influence EH recurrence. Earlier, it was shown that 
dietary folic acid intake decreased the risk of endometrial 
cancer.10 Similar findings were reported by some others25,26 
in which higher folic acid intake accounted for a 20% to 
40% reduced risk for endometrial cancer, but not other 
cancers.27,28 Furthermore, we have previously shown that 
folic acid supplementation (5 mg/d) for 6 months for 
women with cervical intraepithelial neoplasia grade 1 
(CIN1) resulted in its recurrence.29 Improvement in cervical 
dysplasia also associated with folic acid therapy in users of 
oral contraceptives.30 However, folic acid supplementation 
at a dosage of 10 mg/d for 6 months for subjects with CIN1 
or CIN2 did not alter the course of established disease.31 In 
addition, in a meta-analysis study conducted by Qin et al,32 it 
was shown that folic acid supplementation had no significant 
impact on total cancer incidence, colorectal cancer, prostate 
cancer, breast cancer or hematological malignancies, but 
decreased the risk of melanoma. Existing evidence suggest 
that folic acid plays an important role in DNA methylation, 
synthesis and repair. Folic acid intake may reduce cancer risk 
through increased 5-methyltetrahydrofolic acid availability, 
increased values of methionine, and global hypomethylation 
of DNA.14,15 In addition, folic acid supplementation has 
been reported to lower tHcy levels and also may have some 
benefits in patients with EH. In a meta-analysis study, folic 
acid supplementation for patients with type 2 diabetes 
mellitus (T2DM) could reduce tHcy levels.33 Longer 
durations of the treatment and higher dosage of folic acid 
may result in more EH recurrence. 
Effects on Insulin Metabolism and Lipid Profiles
Our data supported that folic acid supplementation for 
subjects with EH for 12 weeks led to a significant reduction 
in FPG, serum insulin, HOMA-IR, triglycerides and 
VLDL-cholesterol levels, and a significant rise in QUICKI, 
but did not affect other lipid profiles. We have previously 
demonstrated that 5 mg/d folic acid supplementation for 
12 weeks for subjects with PCOS had beneficial effects on 
insulin metabolism and total-/HDL-cholesterol ratio, but did 
not affect FPG and other lipid concentrations.34 Supporting 
our results, folic acid supplementation at a dosage of 5 mg/d 
for 8 weeks lowered tHcy, and improved glycemic control 
in subjects with T2DM.35 In addition, in a meta-analysis 
study, folic acid supplementation reduced insulin levels 
and HOMA-IR, but did not affect FPG and HbA1c levels 
among people with metabolic diseases.36 The same findings 
were seen following supplementation with 2.5 mg/d folic 
acid for 3 months in overweight subjects12,  and 7.5 mg/d 
folic acid for 8 weeks in healthy postmenopausal women.37 
Likewise, 5 mg/d folic acid supplementation for 12 weeks 
for subjects with metabolic syndrome improved glycemic 
control, and decreased triglycerides and VLDL-cholesterol 
levels.38 However, taking folic acid supplements at a dosage 
of 5 mg/d by patients with T2DM did not affect glycemic 
control.39 No significant effect on lipid profiles was also seen 
following administration of 5 mg/d folic acid for 4 weeks in 
cigarette smokers.40 There is increasing evidence that insulin 
resistance,41 diabetes and hypertension42 are implicated 
in the etiology and development of endometrial cancer. 
Insulin resistance may act directly on endometrial tissue as 
a mitogenic and anti-apoptotic growth factor.43 Also, higher 
prevalence of hypertension in people with endometrial 
Table 1. General Characteristics of Study Participantsa
Placebo Group 
(n = 30)
Folic Acid Group 
(n = 30)
Age (y) 44.7±3.1 44.4±6.5
Height (cm) 157.9±5.3 156.4±7.6
Weight at study baseline (kg) 76.1±9.2 75.2±12.2
Weight at end-of-trial (kg) 76.3±9.3 75.3±12.1
Weight change (kg) 0.2±0.7 0.1±0.6
BMI at study baseline (kg/m2) 30.5±3.8 30.7±4.6
BMI at end-of-trial (kg/m2) 30.6±3.8 30.8±4.6
BMI change (kg/m2) 0.1±0.3 0.1±0.2
EH recurrence (%) 22 (73.3) 25 (83.3)
EH, endometrial hyperplasia; BMI, Body mass index.
a Data are means± SDs. 
Table 2. Mean Dietary Intakes of Study Participants at Weeks 1, 3, 6, 9 
and 12 of the Studya
Placebo Group
(n = 30)
Folic Acid Group
(n = 30)
Pb
Energy (kcal/d) 2286±130 2242±116 0.17
Carbohydrates (g/d) 312.0±35.8 306.1±42.4 0.56
Protein (g/d) 82.3±10.6 82.5±15.1 0.96
Fat (g/d) 81.9±12.5 79.5±14.4 0.50
SFA (g/d) 23.4±5.4 22.5±6.5 0.55
PUFA (g/d) 28.4±5.9 28.2±6.4 0.92
MUFA (g/d) 21.6±5.1 20.1±5.0 0.25
Cholesterol (mg/d) 189.5±117.9 210.7±146.9 0.54
TDF (g/d) 16.0±4.4 16.1±4.0 0.97
Vitamin B2 (mg/d) 1.6±0.2 1.5±0.2 0.26
Vitamin B6 (mg/d) 1.2±0.3 1.3±0.4 0.30
Folic acid (µg/d) 228.6±89.1 227.7±73.1 0.96
Vitamin B12 (µg/d) 3.7±1.3 3.5±1.4 0.66
MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; 
SFA, saturated fatty acid; TDF, total dietary fiber.
a Data are means± SDs.
bObtained from independent t test. 
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carcinoma may be correlated to hyperinsulinemia.44 
Furthermore, prior studies have shown a decreasing risk 
of CVD following supplementation of folic acid, due to 
reducing tHcy concentrations. For instance, in a meta-
analysis study, folic acid supplementation decreased the 
risk of cardiovascular and cerebrovascular events by 12.9% 
compared with control groups.45 Two meta-analyses have 
documented that folic acid supplementation was beneficial 
for CVD prevention in people with kidney diseases.46,47 
Therefore, due to its beneficial effects on insulin metabolism 
and triglycerides and VLDL-cholesterol levels, folic acid 
may decrease metabolic events related to diabetes and 
CVD in patients with EH. Folic acid intake may improve 
glycemic control and lipid profiles through increasing AMP-
activated protein kinase (AMPK) activation and48 Hcy-
linked effects and also inhibiting insulin-stimulated tyrosine 
phosphorylation of insulin receptor β-subunit and its 
substrates.49 It was suggested that AMPK plays an important 
role in metabolic control, and pharmacologic enhancement 
of AMPK activity is used to improve insulin resistance.48 
Furthermore, it has been documented that in folic acid 
deficiency, homocysteine thiolactone inhibits the tyrosine 
phosphorylation of insulin receptor b-subunit and might 
reduce the p85 regulatory subunit of phosphatidylinositol 
3-kinase activity.50 Hyperhomocysteinemia has been found 
in people with insulin resistance.51,52
Effects on Inflammatory Markers and Oxidative Stress
The current study indicated that taking folic acid by women 
with EH for 12 weeks resulted in a significant decrease in 
serum hs-CRP levels, but did not affect other biomarkers 
of inflammation and oxidative stress. We have previously 
shown that taking folic acid supplements (5 mg/d) for 12 
weeks by subjects with PCOS could decrease serum hs-
CRP and plasma MDA, and increase plasma TAC and 
GSH concentrations.13 In addition, the administration of 
B-group vitamins containing 5 mg folic acid per day for 14 
days resulted in a significant decrease in CRP concentrations 
among subjects with acute ischemic stroke.53 However, in 
elderly subjects with hyperhomocysteinemia, folic acid (400 
µg) and vitamin B12 (500 µg) supplementation did not 
influence either endothelial function or low-grade systemic 
inflammation.54 Furthermore, no significant effect on plasma 
CRP levels was seen after taking 400 µg/d folic acid for 12 
weeks in subjects with atherosclerosis risk factors.55 Increased 
inflammatory cytokines can result in disorders of the 
regulation of cell division, which in turn results in excessive 
mitosis, decreased apoptosis, mutations, and therefore 
initiation and promotion of neoplastic transformations.56 
Furthermore, increased inflammatory markers in EH may 
be considered as a factor in promotion and progression of 
pathology, as well as an attributed risk factor for malignancy 
in EH patients.5 Also, increased levels of free radicals and 
reactive oxygen species seem to be involved in the onset and 
progress of carcinogenesis.47 Therefore, due to its beneficial 
effects on biomarkers of inflammation and oxidative 
stress, folic acid may decrease metabolic complications in 
patients with EH. Less production of parathyroid hormone 
Table 3. Metabolic Profiles at Baseline and After the 12-Week Intervention in Women With Endometrial Hyperplasia That Received Either Folic Acid 
Supplements Or Placeboa
Variables
Placebo Group (n = 30) Folic Acid Group (n = 30)
Difference in Outcome Measures Between 
Folic Acid and Placebo Treatment Groupsb
Baseline Week 12 Baseline Week 12 β (95% CI) P c
tHcy (µmol/L) 19.3±5.7 18.7±5.7 20.5±7.1 16.4±4.4 -0.08 (-0.13, -0.03) 0.001
FPG (mg/dL) 98.4±8.8 99.6±8.0 100.6±12.5 97.2±12.3 -3.99 (-7.39, -0.59) 0.02
Insulin (μIU/mL) 12.1±4.2 12.6±4.7 13.4±5.1 10.7±5.0 -2.82 (-4.86, -0.77) 0.008
HOMA-IR 2.9±1.1 3.1±1.2 3.3±1.4 2.7±1.3 -0.68 (-1.20, -0.17) 0.009
QUICKI 0.32±0.02 0.32±0.01 0.32±0.02 0.33±0.03 0.01 (0.004, 0.03) 0.01
Triglycerides (mg/dL) 134.5±45.4 139.7±45.0 136.0±47.5 124.2±37.0 -16.47 (-28.72, -4.22) 0.009
VLDL-cholesterol (mg/dL) 26.9±9.1 27.9±9.0 27.2±9.5 24.8±7.4 -3.29 (-5.74, -0.84) 0.009
Total cholesterol (mg/dL) 190.0±33.1 194.2±33.5 185.1±32.6 186.9±39.5 -2.77 (-15.42, 9.87) 0.66
LDL-cholesterol (mg/dL) 118.7±33.9 121.2±32.4 113.7±28.9 118.5±39.7 1.74 (-11.24, 14.73) 0.78
HDL-cholesterol (mg/dL) 44.4±7.9 45.0±9.3 44.1±7.6 43.5±7.8 -1.20 (-3.35, 0.94) 0.26
hs-CRP (mg/L) 4.2±2.2 4.4±1.9 3.6±3.6 2.5±4.5 -0.36 (-0.52, -0.21) <0.001
NO (μmol/L) 45.6±7.8 45.3±8.1 50.4±8.0 50.8±5.4 3.04 (0.00, 6.08) 0.05
TAC (mmol/L) 782.7±56.4 786.8±71.5 745.8±42.8 735.9±99.1 -10.86 (-48.66, 26.94) 0.56
GSH (µmol/L) 596.6±90.2 599.1±101.1 676.6±97.3 688.3±107.5 26.55 (-17.71, 70.82) 0.23
MDA (µmol/L) 2.5±0.4 2.5±0.4 2.7±0.3 2.6±0.2 -0.06 (-0.20, 0.08) 0.39
FPG, fasting plasma glucose; GSH, total glutathione; HOMA-IR, homeostasis model assessment for insulin resistance; HDL-cholesterol, high density 
lipoprotein-cholesterol; Hs-CRP, high sensitivity C-reactive protein; LDL-cholesterol, low density lipoprotein-cholesterol; MDA, malondialdehyde; NO, 
nitric oxide; QUICKI, quantitative insulin sensitivity check index; VLDL-cholesterol, very low density lipoprotein-cholesterol; tHcy, total homocysteine; 
TAC, total antioxidant capacity. 
aData are mean ±SDs.
b”Outcome measures” refer to the change in values of measures of interest between baseline and week 12. β (difference in the mean outcomes measures 
between treatment groups [folic acid group = 1 and placebo group = 0]). 
cObtained from multiple regression model (adjusted for baseline values of each biochemical variables, age and baseline BMI).
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(PTH) due to decreased insulin resistance57 following 
supplementation of folic acid may decrease production of 
inflammatory factors. Furthermore, decreased expression of 
inflammatory cytokines due to decreased levels of Hcy and 
decreased activity of nuclear factor kappa B58 by folic acid 
supplementation may decrease inflammatory markers and 
oxidative stress. 
The current study had a number of strengths. Firstly, we 
focused on some interesting questions using a randomized, 
double-blind, placebo-controlled trial. The findings of 
improved glycemic control, triglycerides, VLDL-cholesterol 
and hs-CRP levels in the folic acid group are interesting, 
but need to be confirmed in a larger study. Another strength 
of the current study was the absence of dropout. One 
of the major limitations of this study was the absence of 
measurement of serum levels of folic acid, vitamin B12 
and B6 due to funding limitations. In addition, sample 
size and duration of intervention were not enough in the 
current study. Further studies are needed to confirm our 
findings with a larger sample size and a longer duration of 
the treatment. Also, longer duration of the treatment may 
result in higher EH recurrence.
In conclusion, we found that folic acid administration 
for 12 weeks at a dosage of 5 mg/d for subjects with EH 
improved glycemic control, triglycerides, VLDL-cholesterol, 
hs-CRP and MDA levels, but did not influence recurrence 
and other metabolic profiles. This suggests that folic acid 
supplementation may confer advantageous therapeutic 
potential for women with EH. Further research is needed in 
other populations and for longer periods to determine the 
beneficial effects of folic acid supplementation. Moreover, 
further studies should evaluate gene expression levels related 
to insulin metabolism, inflammation and oxidative stress to 
explore the plausible mechanisms and confirm our findings.
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